Entropy Removal and Coherence with Lasers

The creation of low entropy states is crucial to modern atomic and molecular physics as particle cooling has opened the way for the creation of ultracold superfluid, quantum simulators, and increasing the precision of atomic clocks. However, it is often unclear how the particle ensemble’s entropy is redistributed to other subsystems during the cooling process. Furthermore, experimental control of quantum systems during its interaction with laser fields is often impaired by incoherent, spontaneous processes that may transfer particles to unwanted states. With these points in mind, my honors thesis focuses on protocols that create low entropy states as well as schemes that increase coherent control in quantum evolution. First, we present a method for creating high impulse laser slowing protocols that mitigate the effects of incoherent jumps by evolving the system with an adiabatic shortcut. Once the particles are slowed, they are often cooled using laser fields. This is the process under investigation next as we demonstrate that the laser fields themselves can absorb atomic entropy during their coherent dynamics. We then dedicate our study to the steady-state superradiance model in the weak pumping regime. Here, we investigate the properties of the subradiant state and the appearance of an “enhancement threshold” where the subradiant state may be extracted for high atom numbers in an experimental setting. These states are insensitive to spontaneous emission and can therefore protect the evolution of a system during a quantum metrological process on atomic platforms

Adiabatic Control of Decoherence-Free-Subspaces in an Open Collective System

We propose a method to adiabatically control an atomic ensemble using a decoherence-free subspace (DFS) within a dissipative cavity. We can engineer a specific eigenstate of the system's Lindblad jump operators by injecting a field into the cavity which deconstructively interferes with the emission amplitude of the ensemble. In contrast to previous adiabatic DFS proposals, our scheme creates a DFS in the presence of collective decoherence. We therefore have the ability to engineer states that have high multi-particle entanglements which may be exploited for quantum information science or metrology. We further demonstrate a more optimized driving scheme that utilizes the knowledge of possible diabatic evolution gained from the so-called adiabatic criteria. This allows us to evolve to a desired state with exceptionally high fidelity on a time scale that does not depend on the number of atoms in the ensemble. By engineering the DFS eigenstate adiabatically, our method allows for faster state preparation than previous schemes that rely on damping into a desired state solely using dissipation.Comment: 15 pages and 8 Figure

Optimal Generators for Quantum Sensing

We propose a computationally efficient method to derive the unitary evolution that a quantum state is most sensitive to. This allows one to determine the optimal use of an entangled state for quantum sensing, even in complex systems where intuition from canonical squeezing examples breaks down. In this paper we show that the maximal obtainable sensitivity using a given quantum state is determined by the largest eigenvalue of the quantum Fisher information matrix (QFIM) and, importantly, the corresponding evolution is uniquely determined by the coinciding eigenvector. Since we optimize the process of parameter encoding rather than focusing on state preparation protocols, our scheme is relevant for any quantum sensor. This procedure naturally optimizes multiparameter estimation by determining, through the eigenvectors of the QFIM, the maximal set of commuting observables with optimal sensitivity.Comment: 7 pages, 2 figure

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee